SNAP Update and ResourcesActualización y recursos de SNAP
On November 1, 2025, the requirements to receive and apply to the Supplemental Nutrition Assistance Program (SNAP) benefits have changed. To see the new policies to request SNAP benefits, click here and/or call 211 for SNAP assistance. Learn more
El 1 de noviembre de 2025, cambiaron los requisitos para recibir y aplicar para los beneficios del Programa de Asistencia Nutricional Suplementaria (SNAP, por sus siglas en inglés). Para consultar las nuevas políticas para aplicar para los beneficios de SNAP, haz clic aquí o llama al 211 para obtener ayuda de SNAP. Aprende Más
Transportation UpdateActualización de transporte
Starting December 15, 2025, SafeRide Health will become the new provider for all member rides to doctor appointments and pharmacy visits. After this date, Texas Children’s Health Plan will no longer use MTM for Non Emergency Medical Transportation (NEMT) services.
For other questions, please call Member Services at the number on the back of your member ID card.
A partir del 15 de diciembre de 2025, SafeRide Health será el nuevo proveedor para todos los viajes de los miembros a citas médicas y visitas a la farmacia. Después de esta fecha, Texas Children’s Health Plan ya no usará MTM para los servicios de Transporte Médico No Urgente (NEMT).
Prior Authorization Criteria Update for Breyanzi and Kymriah
Date: July 27, 2022Attention: All ProvidersEffective Date: September 1, 2022Providers should monitor the Texas Children’s Health Plan (TCHP) Provider Portal regularly for alerts and updates associated with the COVID-19 event. TCHP reserves the right to update and/or change this information without prior notice due to the evolving nature of the COVID-19 event.Call to action: Texas Children’s Health Plan (TCHP) would like to inform providers that the Health and Human Services Commission (HHSC) will update the prior authorization criteria for Breyanzi (Q2054) and Kymriah (Q2042) effective September 1, 2022. The U.S. Food and Drug Administration (FDA) has approved additional indications for Breyanzi and Kymriah.
In addition to its current indication, Breyanzi is now approved to treat adult clients 18 years of age and older who have large B-cell lymphoma with the following:
Refractory disease to first-line chemoimmunotherapy or relapses within 12 months of first-line chemoimmunotherapy; or
Refractory disease to first-line chemoimmunotherapy or relapse after first-line chemoimmunotherapy and are not eligible for hematopoietic stem cell transplant (HSCT) due to comorbidities or age; or
Relapsed or refractory disease after two or more lines of systemic therapy.
In addition to its current indication, Kymriah is now approved to treat adult clients 18 years of age and older who have relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.
How this impacts providers: Prior authorization approval for Breyanzi (lisocabtagene maraleucel) treatment in adult clients with large B-cell lymphoma will be considered once all the following criteria are met:
Client is 18 years of age or older
Client must have large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or relapses within 12 months of first-line chemoimmunotherapy
Client has histologically confirmed diagnosis of one of the following:
Client does not have primary central nervous systemlymphoma/disease
Client has not received prior CD-19 directed CAR-Ttherapy
Client does not have an active infection or inflammatory disorder
Prior authorization approval for Kymriah (tisagenlecleucel) treatment in adult clients with relapsed or refractory follicular lymphoma (FL) will be considered once all the following criteria are met:
Client is 18 years of age or older
Client has relapsed or refractory disease after two or more lines of systemic therapy
Client has histologically confirmed diagnosis of one of the following:
